Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
|Videos|November 7, 2014
Dr. Papadimitrakopoulou Provides an Update on Pembrolizumab for Lung Cancer
Author(s)Vassiliki Papadimitrakopoulou, MD
Vassiliki Papadimitrakopoulou, MD, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.
Advertisement
Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.
Pembrolizumab is currently being studied in patients whose tumors express PD-L1. This is a smart enrichment strategy for treating patients, Papadimitrakopoulou says, and the activity seen so far could be because of this selection. However, all evidence so far points to good activity with this agent in all settings of non-small cell lung cancer.
Advertisement
Related to this article
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5